Adult Immunization

Your daily dose of the clinical news you may have missed.

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.

IDWeek2024: The nanoparticle influenza vaccine and combination flu-Covid-19 shot produced immunogenicity comparable to or higher than comparator vaccines.

V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.

Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.